Macrophage Pharma Ltd (MPL) is a leading UK innate immune cell company focused on treating human diseases involving regulated cell death. Macrophage Pharma’s novel approach utilizes its proprietary cell selective small molecule Esterase Sensitive Motif (ESM™) platform to target key pathways involved in regulated cell death.
ESM™ is clinically validated, delivering drugs to cells of myeloid origin with exquisite selectivity resulting in improved pharmacology, efficacy and safety. The approach provides opportunity for both best-in-class drugs against validated targets and first-in-class molecules for highly novel targets.
MPL leadership comprises a highly experienced executive team with a strong entrepreneurial track record in biopharma, a Board of Directors featuring leading figures from the investment community and a Scientific Advisory Board which includes both world class immunologists and oncologists. Together, these capabilities provide MPL with the foundations to deliver novel therapies through high impact science and strong commercial awareness.